Fabrice Cognasse
Overview
Explore the profile of Fabrice Cognasse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
3232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cloutier M, Cognasse F, Yokoyama A, Hazegh K, Mykhailova O, Brandon-Coatham M, et al.
Transfusion
. 2023 Jun;
63(8):1506-1518.
PMID: 37387566
Background: Blood donors at the extremes of the age spectrum (16-19 years vs. ≥75 years) are characterized by increased risks of iron deficiency and anemia, and are often underrepresented in...
12.
Ebermeyer T, Hequet O, Berard F, Prier A, Eyraud M, Arthaud C, et al.
Front Cardiovasc Med
. 2023 May;
10:1094786.
PMID: 37215546
Coronavirus disease (COVID)-19 is characterised in particular by vascular inflammation with platelet activation and endothelial dysfunction. During the pandemic, therapeutic plasma exchange (TPE) was used to reduce the cytokine storm...
13.
Duchez A, Fauteux-Daniel S, Sut C, Ebermeyer T, Heestermans M, Arthaud C, et al.
Front Immunol
. 2023 May;
14:1031968.
PMID: 37138863
Platelet concentrate (PC) transfusion seeks to provide haemostasis in patients presenting severe central thrombocytopenia or severe bleeding. PCs may induce adverse reactions (AR) that can occasionally be severe (SAR). PCs...
14.
Cognasse F, Hamzeh-Cognasse H, Rosa M, Corseaux D, Bonneaudeau B, Pierre C, et al.
EBioMedicine
. 2022 Dec;
87:104414.
PMID: 36535107
Background: COVID-19 convalescent plasma (CCP) contains neutralising anti-SARS-CoV-2 antibodies that may be useful as COVID-19 passive immunotherapy in patients at risk of developing severe disease. Such plasma from convalescent patients...
15.
Cognasse F, Hamzeh Cognasse H, Eyraud M, Prier A, Arthaud C, Tiberghien P, et al.
Transfusion
. 2022 Dec;
63(1):217-228.
PMID: 36453841
Background: Structural and biochemical changes in stored platelets are influenced by collection and processing methods. This international study investigates the effects of platelet (PLT) processing and storage conditions on HMGB1,...
16.
Heestermans M, Poenou G, Duchez A, Hamzeh-Cognasse H, Bertoletti L, Cognasse F
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36361963
Venous thromboembolism (VTE) is the third leading cardiovascular cause of death and is conventionally treated with anticoagulants that directly antagonize coagulation. However, recent data have demonstrated that also platelets play...
17.
Lipidomic analysis of differently prepared platelet concentrates in additive solution during storage
Duchez A, Fauteux-Daniel S, Ebermeyer T, Heestermans M, Arthaud C, Eyraud M, et al.
Blood Transfus
. 2022 Nov;
21(5):409-421.
PMID: 36346879
Background: Structural and biochemical changes in stored platelets are influenced by collection and processing methods. Lesions may appear during platelet concentrate storage, some of which may be involved in adverse...
18.
Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L
Cells
. 2022 Oct;
11(20).
PMID: 36291080
Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent) venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a century, and, nowadays, physicians...
19.
Cognasse F, Hamzeh-Cognasse H, Duchez A, Shurko N, Eyraud M, Arthaud C, et al.
Front Immunol
. 2022 Oct;
13:1034379.
PMID: 36275757
Blood products in therapeutic transfusion are now commonly acknowledged to contain biologically active constituents during the processes of preparation. In the midst of a worldwide COVID-19 pandemic, preliminary evidence suggests...
20.
de Wit Y, Hamzeh-Cognasse H, Cognasse F, Ten Brinke A, Zeerleder S
Transfusion
. 2022 Aug;
62(9):1721-1726.
PMID: 35950480
Background: Patients with severe thrombocytopenia due to bone marrow failure and after chemotherapy are still treated with platelet transfusions. Platelet concentrates (PC) are associated with a high incidence of adverse...